These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 10636570)
1. Intermittent androgen suppression. Too good to be true? Abrahamsson PA Scand J Urol Nephrol Suppl; 1999; 203():45-9. PubMed ID: 10636570 [TBL] [Abstract][Full Text] [Related]
2. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy. Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233 [TBL] [Abstract][Full Text] [Related]
3. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say. Printz C Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668 [No Abstract] [Full Text] [Related]
4. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL; J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219 [TBL] [Abstract][Full Text] [Related]
5. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492 [TBL] [Abstract][Full Text] [Related]
7. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782 [TBL] [Abstract][Full Text] [Related]
8. [Current strategies of intermittent hormone therapy in prostate cancer]. Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677 [TBL] [Abstract][Full Text] [Related]
9. Intermittent androgen deprivation therapy in prostate cancer: is everything so clear? Mottet N Eur Urol; 2013 Jan; 63(1):121-2; discussion 123-4. PubMed ID: 22921963 [No Abstract] [Full Text] [Related]
10. Androgen deprivation for prostate cancer: when and how, the good and the bad. Chi KN; Nguyen PL; Higano CS Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714494 [TBL] [Abstract][Full Text] [Related]